New resolution enhancement mode (REM) for Waters' multi-reflecting time-of-flight (MRT) mass spectrometer leads to greater specificity and higher sample throughput for metabolomics UPLC™-MS/MS and MS imaging studies.

Waters Corporation has announced new updates to its SELECT SERIES™ MRT System that increases its specificity and utility for UPLC-MS/MS metabolomics and drug discovery applications and for mass spectrometry imaging experiments. The MRT System now offers 50% higher resolution, making it capable of 300,000 FWHM resolution, a 3X faster scan rate, and parts-per-billion mass accuracy.

Professor Simona Francese is one of Sheffield-Hallam University's principal investigators whose team's breast cancer proof of concept study in Nature Scientific Reports recently drew national and international media attention. She's eager to investigate how the MRT Systems, which the University's Centre for Mass Spectrometry Imaging recently acquired, can accelerate her research.

"The MRT System's sensitivity, mass accuracy, and resolution gives me considerable hope that it will make a crucial difference with both our forensic and clinical diagnostic research," says Prof. Francese. "We anticipate the instruments will take our 3D cell culture, disease mechanism, and drug distribution collaborative studies to new heights."

The new resolution enhancement mode is available as an optional upgrade to currently installed and new SELECT SERIES MRT Systems.

View Product Information

About Waters Corporation

Waters Corporation (NYSE:WAT), a global leader in analytical instruments and software, has pioneered chromatography, mass spectrometry, and thermal analysis innovations serving the life, materials, and food sciences for over 60 years. With more than 8,200 employees worldwide, Waters operates directly in 35 countries, including 14 manufacturing facilities, and with products available in more than 100 countries.

Waters, UPLC, and SELECT SERIES are trademarks of Waters Corporation.

Recent news from Waters